These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

271 related items for PubMed ID: 9865310

  • 1. Postmarketing evaluation of mycophenolate mofetil-based triple therapy immunosuppression compared with a conventional azathioprine-based regimen reveals enhanced efficacy and early pharmacoeconomic benefit after renal transplantation.
    Wüthrich RP, Weinreich T, Schwarzkopf AK, Candinas D, Binswanger U.
    Transplant Proc; 1998 Dec; 30(8):4096-7. PubMed ID: 9865310
    [No Abstract] [Full Text] [Related]

  • 2. Triple therapy with mycophenolate mofetil versus azathioprine.
    Muñiz ML, Amenabar J, Gómez-Ullate P, Urbizu J, Lampreabe I.
    Transplant Proc; 1999 Dec; 31(1-2):1144-6. PubMed ID: 10083512
    [No Abstract] [Full Text] [Related]

  • 3. Mycophenolate mofetil eliminates the rationale for antilymphocyte induction therapy in nonhaploidentical living-donor kidney transplants.
    Shaffer D, Madras PN, Conway P, Davis C, Simpson MA, Monaco AP.
    Transplant Proc; 1997 Dec; 29(1-2):342-3. PubMed ID: 9123031
    [No Abstract] [Full Text] [Related]

  • 4. Mycophenolate mofetil for the prevention of acute rejection of primary cadaveric kidney transplants: status of the MYC 1866 study at 1 year. The U.S. Mycophenolate Mofetil Study Group.
    Transplant Proc; 1997 Dec; 29(1-2):348-9. PubMed ID: 9123033
    [No Abstract] [Full Text] [Related]

  • 5. Triple therapy with mycophenolate mofetil, cyclosporine, and prednisone in renal transplantation.
    Crespo JF, Górriz JL, Sancho A, Avila A, Alcoy E, Pallardó LM.
    Transplant Proc; 1999 Sep; 31(6):2261-2. PubMed ID: 10500568
    [No Abstract] [Full Text] [Related]

  • 6. Pharmacoeconomic analysis of mycophenolate mofetil versus azathioprine in primary cadaveric renal transplantation.
    Baker GM, Martin JE, Jang R, Schroeder TJ, Armitstead JA, Myre S, First MR.
    Transplant Proc; 1998 Dec; 30(8):4082-4. PubMed ID: 9865304
    [No Abstract] [Full Text] [Related]

  • 7. Selective CellCept therapy in high-risk renal transplant recipients.
    Isenberg A, Singh TP, Shen GK, Freed BM, Conti DJ.
    Transplant Proc; 1998 Jun; 30(4):1188-9. PubMed ID: 9636480
    [No Abstract] [Full Text] [Related]

  • 8. Mycophenolate mofetil as maintenance immunosuppression in pediatric renal transplantation.
    Ettenger R, Cohen A, Nast C, Moulton L, Marik J, Gales B.
    Transplant Proc; 1997 Jun; 29(1-2):340-1. PubMed ID: 9123030
    [No Abstract] [Full Text] [Related]

  • 9. Reduced kidney transplant rejection rate and pharmacoeconomic advantage of mycophenolate mofetil.
    Wüthrich RP, Weinreich T, Ambühl PM, Schwarzkopf AK, Candinas D, Binswanger U.
    Nephrol Dial Transplant; 1999 Feb; 14(2):394-9. PubMed ID: 10069195
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Safety and efficacy of mycophenolate mofetil for prophylaxis in Asian renal transplant recipients.
    Suhail SM, Vathsala A, Lou HX, Woo KT.
    Transplant Proc; 2000 Nov; 32(7):1757-8. PubMed ID: 11119922
    [No Abstract] [Full Text] [Related]

  • 12. Evaluation of various immunosuppressive regimes in second renal transplants.
    Toronyi E, Remport A, Járay J, Máthé Z, Borka P, Perner F.
    Transplant Proc; 2001 May; 33(3):2315-6. PubMed ID: 11377543
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. A prospective randomised study of CSA monotherapy versus CSA plus mycophenolate mofetil in cadaveric renal transplant recipients.
    Sells RA, Bakran A, Brown MW, Grinyo J, Hammad A, Hyatt D, Owens G.
    Transplant Proc; 1998 Dec; 30(8):4098. PubMed ID: 9865311
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Comparison of long-term actual renal allograft survival in mycophenolate mofetil and azathioprine-based triple drug immunosuppression protocols.
    Attallah N, Goggins M, Nori U, Abouljoud M, Zasuwa G, Venkat KK, Parasuraman R.
    Transplant Proc; 2005 Jun; 37(5):2060-2. PubMed ID: 15964338
    [Abstract] [Full Text] [Related]

  • 20. Mycophenolate mofetil for the treatment of a first acute renal allograft rejection: three-year follow-up. The Mycophenolate Mofetil Acute Renal Rejection Study Group.
    Mycophenolate Mofetil Acute Renal Rejection Study Group.
    Transplantation; 2001 Apr 27; 71(8):1091-7. PubMed ID: 11374408
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.